Endo International | ENDP - Sales Revenues


Endo International reported $497.73M in Sales Revenues for its fiscal quarter ending in December of 2023.



Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.8B 500M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Ligand Pharmaceuticals USD 51.72M 7.94M Mar/2026
Merck USD 16.29B 110M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Takeda JPY 1.09T 100B Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Zoetis USD 2.3B 100M Mar/2026